CareDx (CDNA) Misses Q1 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq end lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
CareDx, Inc. Reports First Quarter 2016 Financial Results
May 6, 2016 7:30 AM EDTBRISBANE, Calif., May 06, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today reported financial results for the first quarter ended March 31, 2016.
Recent Highlights
Total revenue for the first quarter of 2016 was $6.6 millionCompleted acquisition of Allenex AB, creating an international transplant diagnostics companyIncreased AlloMap patient results volume by 8% in the first quarter of 2016 compared with the same period in 2015Built further momentum on AlloMap Variability with 41... More